Rycarfa 50 mg tablets for dogs
Rycarfa 50 mg tablets for dogs
Authorised
- Carprofen
Product identification
Medicine name:
Rycarfa 50 mg tablets for dogs
Rycarfa 50 mg Tablet
Rycarfa 50 mg Comprimé
Rycarfa 50 mg Tablette
Active substance:
- Carprofen
Target species:
-
Dog
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Carprofen50.00/milligram(s)1.00Tablet
Pharmaceutical form:
-
Tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QM01AE91
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Belgium
Available in:
-
Belgium
Package description:
- Blister (OPA/Al/PVC-Al): 20 tablets (10 tablets/blister) in a box
- Blister (OPA/Al/PVC-Al): 50 tablets (10 tablets/blister) in a box
- Blister (OPA/Al/PVC-Al): 100 tablets (10 tablets/blister) in a box
- Blister (OPA/Al/PVC-Al): 500 tablets (10 tablets/blister) in a box
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
- KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
- TAD Pharma GmbH
- Krka-Farma d.o.o.
- KRKA tovarna zdravil d.d. Novo mesto
Responsible authority:
- Federal Agency For Medicines And Health Products
Authorisation number:
- BE-V456782
Date of authorisation status change:
Reference member state:
-
Ireland
Procedure number:
- IE/V/0316/002
Concerned member states:
-
Austria
-
Belgium
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Italy
-
Netherlands
-
Norway
-
Portugal
-
Spain
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Package Leaflet
This document does not exist in this language (English). You can find it
in another language below.
Combined File of all Documents
English (PDF)
Download Published on: 24/08/2025
Labelling
This document does not exist in this language (English). You can find it
in another language below.